#525 Impact of BRCA mutation status on efficacy of atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for late-relapsing recurrent ovarian cancer: subgroup analysis of the ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial

Frédéric Selle,Lydia Gaba,Maria-Pilar Barretina-Ginesta,Manuel Rodrigues,Ana Oaknin,Andres Redondo,Toon Van Gorp,Ana Santaballa,Alejandro Pérez-Fidalgo,Michel Fabbro,Luis Miguel De Sande,Maria Jesús Rubio,Mª José Bermejo Pérez,Annamaria Ferrero,Stefan Kommoss,Antonio González-Martín,Rossella Franzini,Margarita Romeo,Jean-Pierre Lotz,Philippe Follana

doi:10.1136/ijgc-2024-esgo.1119

#525 Impact of BRCA mutation status on efficacy of atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for late-relapsing recurrent ovarian cancer: subgroup analysis of the ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial

Frédéric Selle, Lydia Gaba + Show 18 more

https://doi.org/10.1136/ijgc-2024-esgo.1119

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Publication Date: Mar 1, 2024

#Median Progression-free Survival #Maintenance Niraparib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction/BackgroundPrimary results from the ANITA (NCT03598270) phase 3 trial in patients with late-relapsing recurrent ovarian cancer showed no progression-free survival (PFS) improvement with the addition of atezolizumab to platinum-based chemotherapy...

Full Text